Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dale Schenk

Showing results (1-10 of 63) with videos related to

Pageof 7
Sort By:
Nature|September 24, 2004
Hopes remain for an Alzheimer's vaccineDale Schenk
Nature Reviews. Neuroscience|October 3, 2002
Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginningDale Schenk
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 18, 2008
Commentary on "New directions for frontotemporal dementia drug discovery." Do we know enough to develop meaningful treatments for frontotemporal dementia?Dale Schenk
Experimental Neurology|March 30, 2010
Introduction to the special issue of Experimental Neurology on Alzheimer's diseaseDale Schenk
Current Alzheimer Research|July 18, 2006
Treatment of Alzheimer's disease: the beginning of a new eraDale Schenk
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 22, 2008
Current challenges for the successful treatment and prevention of Alzheimer's disease: treating the pathologies of the disease to change its clinical courseDale Schenk
Annual Review of Pharmacology and Toxicology|November 5, 2002
Alzheimer's disease: molecular understanding predicts amyloid-based therapeuticsDennis J Selkoe, Dale Schenk
Current Opinion in Immunology|September 3, 2004
Current progress in beta-amyloid immunotherapyDale Schenk, Michael Hagen, Peter Seubert
Cold Spring Harbor Perspectives in Medicine|September 7, 2012
Treatment strategies targeting amyloid β-proteinDale Schenk, Guriqbal S Basi, Menelas N Pangalos
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 15, 2009
Cytoskeletal modulators and pleiotropic strategies for Alzheimer drug discoveryDale Schenk, Maria C Carrillo, John Q Trojanowski
Pageof 7

Showing results (1-10 of 63) with videos related to

Sort By:
Pageof 7
Nature|September 24, 2004
Hopes remain for an Alzheimer's vaccineDale Schenk
Nature Reviews. Neuroscience|October 3, 2002
Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginningDale Schenk
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 18, 2008
Commentary on "New directions for frontotemporal dementia drug discovery." Do we know enough to develop meaningful treatments for frontotemporal dementia?Dale Schenk
Experimental Neurology|March 30, 2010
Introduction to the special issue of Experimental Neurology on Alzheimer's diseaseDale Schenk
Current Alzheimer Research|July 18, 2006
Treatment of Alzheimer's disease: the beginning of a new eraDale Schenk
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 22, 2008
Current challenges for the successful treatment and prevention of Alzheimer's disease: treating the pathologies of the disease to change its clinical courseDale Schenk
Annual Review of Pharmacology and Toxicology|November 5, 2002
Alzheimer's disease: molecular understanding predicts amyloid-based therapeuticsDennis J Selkoe, Dale Schenk
Current Opinion in Immunology|September 3, 2004
Current progress in beta-amyloid immunotherapyDale Schenk, Michael Hagen, Peter Seubert
Cold Spring Harbor Perspectives in Medicine|September 7, 2012
Treatment strategies targeting amyloid β-proteinDale Schenk, Guriqbal S Basi, Menelas N Pangalos
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 15, 2009
Cytoskeletal modulators and pleiotropic strategies for Alzheimer drug discoveryDale Schenk, Maria C Carrillo, John Q Trojanowski
Pageof 7